What are the Unique Selling Points of USP1 for Synthetic Lethality?
Time: 2:45 pm
day: Day One Track B PM
Details:
• Updates for novel selective USP1 inhibitors in BRCA1-deficient cells for patients who do not respond to PARP inhibitors
• Exploring updates for molecules with ADME properties and PK profiles
• Unearth data for potential monotherapy and combination therapies of USP1 inhibitors
